Premium
Sunlight or diet: what is the answer for providing sufficient vitamin D in the U.K.?
Author(s) -
Macdonald H.M.,
Mavroeidi A.,
Reid D.M.,
Fraser W.D.
Publication year - 2010
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2010.09901.x
Subject(s) - sunlight , vitamin d and neurology , sun exposure , vitamin , chemistry , endocrinology , medicine , zoology , physics , biology , dermatology , optics
1 Leonardi CL, Kimball AB, Papp KA et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin12 ⁄23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665–74. 2 Papp KA, Langley RG, Lebwohl M et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin12 ⁄23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675–84. 3 Smith CH, Anstey AV, Barker JNWN et al. British Assosiation of Dermatologists guidelines for biologics intervention for psoriasis. Br J Dermatol 2009; 161:987–1019. 4 Downs AM. Switching between anti tumour necrosis factor agents – is patient weight an important consideration? Br J Dermatol 2009; 160:1123–34. 5 Gisondi P, Cotena C, Tessari G et al. Anti-tumour necrosis factoralpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22:341–4. 6 Saraceno R, Schipani C, Mazzotta A et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57:290–5. 7 Esposito M, Mazzotta A, Saraceno R et al. Influence and variation of the body mass index in patients treated with etanercept for plaquetype psoriasis. Int J Immunopathol Pharmacol 2009; 22:219–25. 8 Warner JP. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J Endocrinol 2003; 177:351–5. 9 Cathorn WP, Sethi JK. TNF-alpha and adipocyte biology. FEBS Lett 2008; 582:117–31. 10 Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of ustekinumab, a human interleukin-12 ⁄23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008; 135:1130–41. 11 Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12 ⁄23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633–40.